SCHEMBL25551963

SCHEMBL25551963

Cc1cnc(Cl)nc1-c1cnccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.37
RECQL P46063 1/20 0.37
CYP1A2 P05177 1/20 0.37
PIM1 P11309 1/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
ADORA2A P29274 2/20 0.35
ADORA1 P30542 1/20 0.35
P2RX7 Q99572 1/20 0.33
RPS6KA5 O75582 1/20 0.33
ALDH1A1 P00352 1/20 0.33
NISCH Q9Y2I1 1/20 0.33
PDK1 Q15118 2/20 0.32
PDK2 Q15119 1/20 0.32
PDK3 Q15120 1/20 0.32
PDK4 Q16654 1/20 0.32
HRH3 Q9Y5N1 2/20 0.32
NR1H4 Q96RI1 1/20 0.32
CDC7 O00311 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30037736 1.00 HTT (0.37) HTTRECQLCYP1A2PIM1RAB9A
SCHEMBL25559811 0.81 HTT (0.39) HTTRECQLCYP1A2PIM1RAB9A
SCHEMBL25551891 0.81 RPS6KA5 (0.42) HTTRECQLCYP1A2RAB9ANPC1
SCHEMBL23494350 0.79 HTT (0.41) HTTRECQLCYP1A2PIM1ADORA2A
SCHEMBL4540085 0.77 KDM4E (0.54) HTTCYP1A2PIM1RAB9ANPC1
SCHEMBL30036272 0.77 KDM4E (0.41) HTTRECQLCYP1A2PIM1RAB9A
SCHEMBL25551961 0.77 KDM4E (0.41) HTTRECQLCYP1A2PIM1RAB9A
SCHEMBL25559975 0.76 HTT (0.36) HTTRECQLCYP1A2PIM1ADORA2A
SCHEMBL30037613 0.73 CDC7 (0.40) HTTRECQLRAB9AALDH1A1CDC7
SCHEMBL25551967 0.73 CDC7 (0.40) HTTRECQLRAB9AALDH1A1CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 US disclosed
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 HTT 727/4885RECQL 1991/4885CYP1A2 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.